NEWS & MEDIA
GlobeNewswire
29 APRIL 2021
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
Business Wire
April 15 2020
UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
Intrado GlobeNewswire
11 March 2020
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
Intrado GlobeNewswire
11 March 2020
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
Business Wire
9 MARCH 2020
Arkin Holdings Raises $140 Million in Second Partnership Arkin Bio-Ventures II to Invest in Groundbreaking Pharma and Biotechnology Companies
CISION PR NEWSWIRE
30 JULY 2018
BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
CISION PR NEWSWIRE
12 MARCH 2018
Cogentix Medical Enters Definitive Merger Agreement to be Acquired by Laborie Medical Technologies for a Purchase Price of $3.85 Per Share in Cash
NASDAQ GLOBE NEWSWIRE
05 FEBRUARY 2018
Sol-Gel Technologies Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NASDAQ GLOBE NEWSWIRE
5 JANUARY 2018
Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)
YAHOO FINANCE
14 DECEMBER 2017
BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia
PR NEWSWIRE
16 MAY 2016
Arkin Holdings and Primera Capital Lead an Investment of $13M in BioSight for an Innovative Treatment of Acute Leukemia
